Building Your Care Team: Therapies and Treatments
Last updated:
While there is no cure for Fragile X syndrome, a multidisciplinary approach combining occupational, speech, and behavioral therapies with symptom-management medications is highly effective. A robust care team includes developmental pediatricians, therapists, and specialized medical providers.
Key Takeaways
- • Therapy is the primary treatment for Fragile X syndrome, including occupational, speech, behavioral, and physical therapies.
- • A multidisciplinary care team is essential for managing symptoms, often led by a developmental pediatrician.
- • Doctors frequently prescribe off-label medications like SSRIs or stimulants to manage anxiety and ADHD symptoms.
- • Experimental targeted therapies, such as PDE4D inhibitors, are currently being researched in clinical trials to improve cognitive function.
While there is currently no “cure” that fixes the underlying FMR1 gene, the standard of care for Fragile X Syndrome (FXS) is robust and effective. It focuses on a multidisciplinary approach—treating the symptoms to improve your child’s independence, communication, and quality of life [1][2]. The most successful plans combine therapeutic interventions with carefully monitored medical care [3][4].
The Foundation: Non-Pharmacological Therapies
Therapy is the first line of management for FXS. These interventions help the brain find new ways to process information and interact with the world [1][5].
- Occupational Therapy (OT): Focuses on sensory processing and fine motor skills. OT is vital for helping children manage sensory hyperarousal (feeling overwhelmed by noise or touch) [1][4].
- Speech-Language Therapy: Addresses delays in expressive and receptive language. Many families also use Augmentative and Alternative Communication (AAC) tools, like picture boards or tablets, to help children express themselves [6][3].
- Behavioral Therapy: Function-based interventions (such as ABA) are highly effective for reducing challenging behaviors or behaviors that interfere with safety (like aggression or self-injury) by teaching alternative ways to communicate needs [7][8].
- Physical Therapy (PT): Helps with “gross motor” skills, such as walking and balance, which can be affected by low muscle tone or flexible joints [1].
The Care Team Roster
Managing FXS requires a “team” of experts working together. You may want to include the following specialists in your child’s circle [2][3][4]:
- Developmental Pediatrician: Often the “quarterback” of the team, overseeing overall growth and development.
- Geneticist/Genetic Counselor: For initial diagnosis and to help family members understand their own risks.
- Neurologist: Specifically if your child experiences seizures (common in about 15% of males with FXS).
- Child Psychiatrist: To manage medications for anxiety, ADHD, or mood.
- Special Education Team: To create an IEP (Individualized Education Program) tailored to how children with FXS learn.
Medications: Treating the Symptoms
There is no “Fragile X pill,” so doctors use “off-label” medications—drugs approved for other conditions that are known to help with FXS symptoms [9][5].
- For Anxiety: SSRIs (Selective Serotonin Reuptake Inhibitors) like sertraline (Zoloft) are the most common [9][1].
- For ADHD: Stimulants (like methylphenidate) or alpha-agonists (like clonidine or guanfacine) help with hyperactivity and focus [9][10].
- For Aggression/Irritability: These are not first-line treatments for young children. If behaviors like aggression or self-injury become severe in older children or teens, “atypical antipsychotics” like aripiprazole (Abilify) or risperidone (Risperdal) may be considered [9][5]. Important Note: These medications carry high risks for metabolic syndrome, including substantial weight gain and increased diabetes risk. They require active monitoring of your child’s diet and regular pediatric lab work [9].
The Future: Targeted Therapies
Researchers are working on “targeted therapies”—drugs designed to fix the specific chemical imbalances in the Fragile X brain [11][12].
- PDE4D Inhibitors (Zatolmilast): This is one of the most promising areas of current research. In Phase 2 clinical trials, this medication (also known as BPN14770) showed potential for improving cognitive performance and daily functioning in males with FXS [11][13].
- Other Trials: Research continues into GABA modulators, metformin, and even CBD, though these are not yet standard treatments [1][14].
Participating in a clinical trial is a personal family decision and an opportunity to contribute to the future of Fragile X care [15].
Frequently Asked Questions
What are the best therapies for a child with Fragile X syndrome?
Are there medications that cure Fragile X syndrome?
What kind of doctors should be on my child's Fragile X care team?
How does occupational therapy help with Fragile X syndrome?
What is Zatolmilast and how does it treat Fragile X?
Questions for Your Doctor
- • Can you help us prioritize which therapy (Speech, OT, or Behavioral) my child needs most right now to see the best progress?
- • Which 'off-label' medications do you have the most experience using for anxiety or ADHD in children with Fragile X?
- • Is there a Fragile X Clinic or a developmental specialist in our area who can serve as the 'hub' for our multidisciplinary team?
- • What are the specific side effects we should watch for if we start a medication like sertraline or a stimulant?
- • Are there any active clinical trials, such as those for PDE4D inhibitors, that my child might be eligible for?
Questions for You
- • Which of my child's symptoms (e.g., anxiety, physical coordination, or communication) is currently impacting our daily life the most?
- • Do I feel like my child's current school or early intervention plan is adequately addressing their specific Fragile X needs?
- • How am I tracking my child's response to new therapies or medications to share with the care team?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
State-of-the-art therapies for fragile X syndrome.
Protic D, Hagerman R
Developmental medicine and child neurology 2024; (66(7)):863-871 doi:10.1111/dmcn.15885.
PMID: 38385885 - 2
New Therapeutic Options for Fragile X Syndrome.
Jalnapurkar I, Cochran DM, Frazier JA
Current treatment options in neurology 2019; (21(3)):12 doi:10.1007/s11940-019-0551-8.
PMID: 30809735 - 3
Fragile X syndrome: genetic and clinical profile in the Hong Kong Chinese population.
Au CWM, Luk HM, Ho S, et al.
Hong Kong medical journal = Xianggang yi xue za zhi 2025; (31(3)):199-207 doi:10.12809/hkmj2411942.
PMID: 40468528 - 4
Consensus Statement of the Indian Academy of Pediatrics on Diagnosis and Management of Fragile X Syndrome in India.
Sachdeva A, Jain P, Gunasekaran V, et al.
Indian pediatrics 2019; (56(3)):221-228.
PMID: 30954995 - 5
Behavioural difficulties in fragile X syndrome: current pharmacological options and potential future developments.
Stanfield AC, McKechanie AG
Expert review of neurotherapeutics 2025; (25(7)):857-867 doi:10.1080/14737175.2025.2510408.
PMID: 40462554 - 6
Parent Perspectives on Augmentative and Alternative Communication Integration for Children With Fragile X Syndrome: It Starts in the Home.
Schladant M, Dowling M
Intellectual and developmental disabilities 2020; (58(5)):409-421 doi:10.1352/1934-9556-58.5.409.
PMID: 33032315 - 7
Functional analysis and treatment of problem behavior exhibited by children with fragile X syndrome.
Kurtz PF, Chin MD, Robinson AN, et al.
Research in developmental disabilities 2015; (43-44()):150-66.
PMID: 26183339 - 8
Conducting In-Home Functional Analyses of Aggression and Self-Injury Exhibited by Boys with Fragile X Syndrome.
Monlux KD, Pollard JS, Bujanda Rodriguez AY, Hall SS
Journal of developmental and behavioral pediatrics : JDBP 2022; (43(4)):e237-e245 doi:10.1097/DBP.0000000000001019.
PMID: 34711767 - 9
Psychotropic Drug Treatment Patterns in Persons with Fragile X Syndrome.
Dominick KC, Andrews HF, Kaufmann WE, et al.
Journal of child and adolescent psychopharmacology 2021; (31(10)):659-669 doi:10.1089/cap.2021.0042.
PMID: 34818076 - 10
Effects of clonidine on progressive ratio schedule performance in Fmr1 knockout mice.
Wrenn CC, French E, Baker D, et al.
Psychopharmacology 2021; (238(4)):1133-1140 doi:10.1007/s00213-021-05760-8.
PMID: 33449137 - 11
Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.
Berry-Kravis EM, Harnett MD, Reines SA, et al.
Nature medicine 2021; (27(5)):862-870 doi:10.1038/s41591-021-01321-w.
PMID: 33927413 - 12
The Emerging Role of Phosphodiesterase Inhibitors in Fragile X Syndrome and Autism Spectrum Disorder.
Thomas SD, Mohammed HA, Hamad MIK, et al.
Pharmaceuticals (Basel, Switzerland) 2025; (18(10)) doi:10.3390/ph18101507.
PMID: 41155624 - 13
ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers.
Norris JE, Berry-Kravis EM, Harnett MD, et al.
Translational psychiatry 2025; (15(1)):323 doi:10.1038/s41398-025-03558-2.
PMID: 40877251 - 14
Dietary fish oil improves autistic behaviors and gut homeostasis by altering the gut microbial composition in a mouse model of fragile X syndrome.
Guo P, Yang X, Guo X, et al.
Brain, behavior, and immunity 2023; (110()):140-151 doi:10.1016/j.bbi.2023.02.019.
PMID: 36858183 - 15
Emerging autism and Fragile X syndrome treatments.
Parkhill M, Salmaso N, D'Angiulli A, et al.
Trends in pharmacological sciences 2025; (46(4)):357-371 doi:10.1016/j.tips.2025.02.004.
PMID: 40102109
This page provides educational information about Fragile X syndrome treatments and therapies. It is not a substitute for professional medical advice, diagnosis, or treatment for your child.
Stay up to date
Get notified when new research about Fragile X syndrome is published.
No spam. Unsubscribe anytime.